123 related articles for article (PubMed ID: 35219181)
1. Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity.
Kuriwaki I; Kameda M; Iikubo K; Hisamichi H; Kawamoto Y; Kikuchi S; Moritomo H; Terasaka T; Iwai Y; Noda A; Tomiyama H; Kikuchi A; Hirano M
Bioorg Med Chem; 2022 Apr; 59():116657. PubMed ID: 35219181
[TBL] [Abstract][Full Text] [Related]
2. Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity.
Yunomae K; Ichisaki S; Matsuo J; Nagayama S; Fukuzaki K; Nagata R; Kito G
J Appl Toxicol; 2007; 27(1):78-85. PubMed ID: 17146843
[TBL] [Abstract][Full Text] [Related]
3. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
[TBL] [Abstract][Full Text] [Related]
4. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
[TBL] [Abstract][Full Text] [Related]
5. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.
Futami T; Okada H; Kihara R; Kawase T; Nakayama A; Suzuki T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Mol Cancer Ther; 2017 Jan; 16(1):68-75. PubMed ID: 27837028
[TBL] [Abstract][Full Text] [Related]
6. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
7. Regulation of hERG and hEAG channels by Src and by SHP-1 tyrosine phosphatase via an ITIM region in the cyclic nucleotide binding domain.
Schlichter LC; Jiang J; Wang J; Newell EW; Tsui FW; Lam D
PLoS One; 2014; 9(2):e90024. PubMed ID: 24587194
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
Sánchez-Chapula JA; Navarro-Polanco RA; Culberson C; Chen J; Sanguinetti MC
J Biol Chem; 2002 Jun; 277(26):23587-95. PubMed ID: 11960982
[TBL] [Abstract][Full Text] [Related]
9. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
Ganapathi SB; Kester M; Elmslie KS
Am J Physiol Cell Physiol; 2009 Apr; 296(4):C701-10. PubMed ID: 19244476
[TBL] [Abstract][Full Text] [Related]
10. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
Zeng H; Lozinskaya IM; Lin Z; Willette RN; Brooks DP; Xu X
J Pharmacol Exp Ther; 2006 Nov; 319(2):957-62. PubMed ID: 16928897
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
[TBL] [Abstract][Full Text] [Related]
12. Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels.
Zhang DY; Wang Y; Lau CP; Tse HF; Li GR
Cell Signal; 2008 Oct; 20(10):1815-21. PubMed ID: 18617000
[TBL] [Abstract][Full Text] [Related]
13. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656.
Siebrands CC; Schmitt N; Friederich P
Anesthesiology; 2005 Jul; 103(1):102-12. PubMed ID: 15983462
[TBL] [Abstract][Full Text] [Related]
14. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
[TBL] [Abstract][Full Text] [Related]
15. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
[TBL] [Abstract][Full Text] [Related]
16. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.
Kamaura M; Kubo O; Sugimoto H; Noguchi N; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Murata T; Sato K
Bioorg Med Chem; 2021 Mar; 34():116034. PubMed ID: 33548803
[TBL] [Abstract][Full Text] [Related]
18. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
19. The Human Ether-a-go-go-related Gene (hERG) Potassium Channel Represents an Unusual Target for Protease-mediated Damage.
Lamothe SM; Guo J; Li W; Yang T; Zhang S
J Biol Chem; 2016 Sep; 291(39):20387-401. PubMed ID: 27502273
[TBL] [Abstract][Full Text] [Related]
20. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Xia M; Shahane SA; Huang R; Titus SA; Shum E; Zhao Y; Southall N; Zheng W; Witt KL; Tice RR; Austin CP
Toxicol Appl Pharmacol; 2011 May; 252(3):250-8. PubMed ID: 21362439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
